Is Dutch Govt Pursuing Wider EU Discussion And Collaboration On Pricing and Reimbursement?
Executive Summary
An initiative from the Netherlands to ensure that pharmaceutical companies market centrally approved medicines in all EU member states is probably intended to fuel discussions on the differences in national pricing and reimbursement policies, says a legal expert.
You may also be interested in...
Is Europe’s BeNeLuxA Coalition Moving Too Fast?
The BeNeLuxA initiative for improving access to medicines could soon include more countries, but much about the collaboration remains opaque for the pharmaceutical industry. Lawyer Koosje van Lessen Kloeke says constructive dialogue between the initiative and industry would benefit the collaboration.
France In Talks With BeNeLuxA Access To Meds Coalition; Group Plans Expansion Beyond EU
The BeNeLuxA collaboration for sustainable access to medicines may soon expand further. Future partners could include France and non-EU markets.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.